Global Community-acquired Bacterial Pneumonia Market Research Report 2023

Community-acquired Bacterial Pneumonia Market

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

The global Community-acquired Bacterial Pneumonia market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Community-acquired Bacterial Pneumonia is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Community-acquired Bacterial Pneumonia is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Community-acquired Bacterial Pneumonia in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Community-acquired Bacterial Pneumonia include Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A. and Pfizer Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Community-acquired Bacterial Pneumonia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community-acquired Bacterial Pneumonia.

The Community-acquired Bacterial Pneumonia market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Community-acquired Bacterial Pneumonia market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Community-acquired Bacterial Pneumonia companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Community-acquired Bacterial Pneumonia Market Report

Core Chapters

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Pleuromutilin Antibiotic

1.2.3 Cephalosporin

1.2.4 Glycylcycline

1.2.5 Oxazolidinone

1.2.6 Ketolide

1.2.7 Others

1.3 Market by Application

1.3.1 Global Community-acquired Bacterial Pneumonia Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Community-acquired Bacterial Pneumonia Market Perspective (2018-2029)

2.2 Community-acquired Bacterial Pneumonia Growth Trends by Region

2.2.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Community-acquired Bacterial Pneumonia Historic Market Size by Region (2018-2023)

2.2.3 Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2024-2029)

2.3 Community-acquired Bacterial Pneumonia Market Dynamics

2.3.1 Community-acquired Bacterial Pneumonia Industry Trends

2.3.2 Community-acquired Bacterial Pneumonia Market Drivers

2.3.3 Community-acquired Bacterial Pneumonia Market Challenges

2.3.4 Community-acquired Bacterial Pneumonia Market Restraints

3.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue

3.1.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue (2018-2023)

3.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2018-2023)

3.2 Global Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Community-acquired Bacterial Pneumonia Revenue

3.4 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio

3.4.1 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Community-acquired Bacterial Pneumonia Revenue in 2022

3.5 Community-acquired Bacterial Pneumonia Key Players Head office and Area Served

3.6 Key Players Community-acquired Bacterial Pneumonia Product Solution and Service

3.7 Date of Enter into Community-acquired Bacterial Pneumonia Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Type (2018-2023)

4.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2024-2029)

5.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Application (2018-2023)

5.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2024-2029)

6.1 North America Community-acquired Bacterial Pneumonia Market Size (2018-2029)

6.2 North America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023)

6.4 North America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Community-acquired Bacterial Pneumonia Market Size (2018-2029)

7.2 Europe Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023)

7.4 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size (2018-2029)

8.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023)

8.4 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Community-acquired Bacterial Pneumonia Market Size (2018-2029)

9.2 Latin America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023)

9.4 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2018-2029)

10.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023)

10.4 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Nabriva Therapeutics

11.1.1 Nabriva Therapeutics Company Detail

11.1.2 Nabriva Therapeutics Business Overview

11.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Introduction

11.1.4 Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.1.5 Nabriva Therapeutics Recent Development

11.2 Paratek Pharmaceuticals

11.2.1 Paratek Pharmaceuticals Company Detail

11.2.2 Paratek Pharmaceuticals Business Overview

11.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction

11.2.4 Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.2.5 Paratek Pharmaceuticals Recent Development

11.3 Melinta Therapeutics

11.3.1 Melinta Therapeutics Company Detail

11.3.2 Melinta Therapeutics Business Overview

11.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Introduction

11.3.4 Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.3.5 Melinta Therapeutics Recent Development

11.4 Allergan plc

11.4.1 Allergan plc Company Detail

11.4.2 Allergan plc Business Overview

11.4.3 Allergan plc Community-acquired Bacterial Pneumonia Introduction

11.4.4 Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.4.5 Allergan plc Recent Development

11.5 Bayer AG

11.5.1 Bayer AG Company Detail

11.5.2 Bayer AG Business Overview

11.5.3 Bayer AG Community-acquired Bacterial Pneumonia Introduction

11.5.4 Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.5.5 Bayer AG Recent Development

11.6 Lupin Pharmaceuticals

11.6.1 Lupin Pharmaceuticals Company Detail

11.6.2 Lupin Pharmaceuticals Business Overview

11.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction

11.6.4 Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.6.5 Lupin Pharmaceuticals Recent Development

11.7 Mylan N.V.

11.7.1 Mylan N.V. Company Detail

11.7.2 Mylan N.V. Business Overview

11.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Introduction

11.7.4 Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.7.5 Mylan N.V. Recent Development

11.8 Sanofi S.A.

11.8.1 Sanofi S.A. Company Detail

11.8.2 Sanofi S.A. Business Overview

11.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Introduction

11.8.4 Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.8.5 Sanofi S.A. Recent Development

11.9 Pfizer Inc.

11.9.1 Pfizer Inc. Company Detail

11.9.2 Pfizer Inc. Business Overview

11.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Introduction

11.9.4 Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.9.5 Pfizer Inc. Recent Development

11.10 Dainippon Sumitomo Pharma

11.10.1 Dainippon Sumitomo Pharma Company Detail

11.10.2 Dainippon Sumitomo Pharma Business Overview

11.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Introduction

11.10.4 Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.10.5 Dainippon Sumitomo Pharma Recent Development

11.11 Takeda Pharmaceutical Company Limited

11.11.1 Takeda Pharmaceutical Company Limited Company Detail

11.11.2 Takeda Pharmaceutical Company Limited Business Overview

11.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Introduction

11.11.4 Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.11.5 Takeda Pharmaceutical Company Limited Recent Development

11.12 Basilea Pharmaceutica International AG

11.12.1 Basilea Pharmaceutica International AG Company Detail

11.12.2 Basilea Pharmaceutica International AG Business Overview

11.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Introduction

11.12.4 Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023)

11.12.5 Basilea Pharmaceutica International AG Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Pleuromutilin Antibiotic

    Table 3. Key Players of Cephalosporin

    Table 4. Key Players of Glycylcycline

    Table 5. Key Players of Oxazolidinone

    Table 6. Key Players of Ketolide

    Table 7. Key Players of Others

    Table 8. Global Community-acquired Bacterial Pneumonia Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Community-acquired Bacterial Pneumonia Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 10. Global Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023) & (US$ Million)

    Table 11. Global Community-acquired Bacterial Pneumonia Market Share by Region (2018-2023)

    Table 12. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 13. Global Community-acquired Bacterial Pneumonia Market Share by Region (2024-2029)

    Table 14. Community-acquired Bacterial Pneumonia Market Trends

    Table 15. Community-acquired Bacterial Pneumonia Market Drivers

    Table 16. Community-acquired Bacterial Pneumonia Market Challenges

    Table 17. Community-acquired Bacterial Pneumonia Market Restraints

    Table 18. Global Community-acquired Bacterial Pneumonia Revenue by Players (2018-2023) & (US$ Million)

    Table 19. Global Community-acquired Bacterial Pneumonia Market Share by Players (2018-2023)

    Table 20. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2022)

    Table 21. Ranking of Global Top Community-acquired Bacterial Pneumonia Companies by Revenue (US$ Million) in 2022

    Table 22. Global 5 Largest Players Market Share by Community-acquired Bacterial Pneumonia Revenue (CR5 and HHI) & (2018-2023)

    Table 23. Key Players Headquarters and Area Served

    Table 24. Key Players Community-acquired Bacterial Pneumonia Product Solution and Service

    Table 25. Date of Enter into Community-acquired Bacterial Pneumonia Market

    Table 26. Mergers & Acquisitions, Expansion Plans

    Table 27. Global Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & (US$ Million)

    Table 28. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2018-2023)

    Table 29. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 30. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2024-2029)

    Table 31. Global Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & (US$ Million)

    Table 32. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2018-2023)

    Table 33. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 34. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2024-2029)

    Table 35. North America Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. North America Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & (US$ Million)

    Table 37. North America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & (US$ Million)

    Table 40. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029) & (US$ Million)

    Table 41. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2018-2023) & (US$ Million)

    Table 43. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2024-2029) & (US$ Million)

    Table 44. Latin America Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029) & (US$ Million)

    Table 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 48. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2024-2029) & (US$ Million)

    Table 50. Nabriva Therapeutics Company Detail

    Table 51. Nabriva Therapeutics Business Overview

    Table 52. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product

    Table 53. Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 54. Nabriva Therapeutics Recent Development

    Table 55. Paratek Pharmaceuticals Company Detail

    Table 56. Paratek Pharmaceuticals Business Overview

    Table 57. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product

    Table 58. Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 59. Paratek Pharmaceuticals Recent Development

    Table 60. Melinta Therapeutics Company Detail

    Table 61. Melinta Therapeutics Business Overview

    Table 62. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product

    Table 63. Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 64. Melinta Therapeutics Recent Development

    Table 65. Allergan plc Company Detail

    Table 66. Allergan plc Business Overview

    Table 67. Allergan plc Community-acquired Bacterial Pneumonia Product

    Table 68. Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 69. Allergan plc Recent Development

    Table 70. Bayer AG Company Detail

    Table 71. Bayer AG Business Overview

    Table 72. Bayer AG Community-acquired Bacterial Pneumonia Product

    Table 73. Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 74. Bayer AG Recent Development

    Table 75. Lupin Pharmaceuticals Company Detail

    Table 76. Lupin Pharmaceuticals Business Overview

    Table 77. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product

    Table 78. Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 79. Lupin Pharmaceuticals Recent Development

    Table 80. Mylan N.V. Company Detail

    Table 81. Mylan N.V. Business Overview

    Table 82. Mylan N.V. Community-acquired Bacterial Pneumonia Product

    Table 83. Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 84. Mylan N.V. Recent Development

    Table 85. Sanofi S.A. Company Detail

    Table 86. Sanofi S.A. Business Overview

    Table 87. Sanofi S.A. Community-acquired Bacterial Pneumonia Product

    Table 88. Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 89. Sanofi S.A. Recent Development

    Table 90. Pfizer Inc. Company Detail

    Table 91. Pfizer Inc. Business Overview

    Table 92. Pfizer Inc. Community-acquired Bacterial Pneumonia Product

    Table 93. Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 94. Pfizer Inc. Recent Development

    Table 95. Dainippon Sumitomo Pharma Company Detail

    Table 96. Dainippon Sumitomo Pharma Business Overview

    Table 97. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product

    Table 98. Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 99. Dainippon Sumitomo Pharma Recent Development

    Table 100. Takeda Pharmaceutical Company Limited Company Detail

    Table 101. Takeda Pharmaceutical Company Limited Business Overview

    Table 102. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product

    Table 103. Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 104. Takeda Pharmaceutical Company Limited Recent Development

    Table 105. Basilea Pharmaceutica International AG Company Detail

    Table 106. Basilea Pharmaceutica International AG Business Overview

    Table 107. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product

    Table 108. Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2018-2023) & (US$ Million)

    Table 109. Basilea Pharmaceutica International AG Recent Development

    Table 110. Research Programs/Design for This Report

    Table 111. Key Data Information from Secondary Sources

    Table 112. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Community-acquired Bacterial Pneumonia Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Community-acquired Bacterial Pneumonia Market Share by Type: 2022 VS 2029

    Figure 3. Pleuromutilin Antibiotic Features

    Figure 4. Cephalosporin Features

    Figure 5. Glycylcycline Features

    Figure 6. Oxazolidinone Features

    Figure 7. Ketolide Features

    Figure 8. Others Features

    Figure 9. Global Community-acquired Bacterial Pneumonia Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 10. Global Community-acquired Bacterial Pneumonia Market Share by Application: 2022 VS 2029

    Figure 11. Hospital Pharmacies Case Studies

    Figure 12. Retail Pharmacies Case Studies

    Figure 13. Online Pharmacies Case Studies

    Figure 14. Community-acquired Bacterial Pneumonia Report Years Considered

    Figure 15. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 16. Global Community-acquired Bacterial Pneumonia Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 17. Global Community-acquired Bacterial Pneumonia Market Share by Region: 2022 VS 2029

    Figure 18. Global Community-acquired Bacterial Pneumonia Market Share by Players in 2022

    Figure 19. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2022)

    Figure 20. The Top 10 and 5 Players Market Share by Community-acquired Bacterial Pneumonia Revenue in 2022

    Figure 21. North America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. North America Community-acquired Bacterial Pneumonia Market Share by Country (2018-2029)

    Figure 23. United States Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Canada Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Europe Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Europe Community-acquired Bacterial Pneumonia Market Share by Country (2018-2029)

    Figure 27. Germany Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. France Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. U.K. Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Italy Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Russia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Nordic Countries Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Region (2018-2029)

    Figure 35. China Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Japan Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. South Korea Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Southeast Asia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. India Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Australia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Latin America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Latin America Community-acquired Bacterial Pneumonia Market Share by Country (2018-2029)

    Figure 43. Mexico Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Brazil Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2018-2029)

    Figure 47. Turkey Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 48. Saudi Arabia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 49. Nabriva Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 50. Paratek Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 51. Melinta Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 52. Allergan plc Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 53. Bayer AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 54. Lupin Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 55. Mylan N.V. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 56. Sanofi S.A. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 57. Pfizer Inc. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 58. Dainippon Sumitomo Pharma Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 59. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 60. Basilea Pharmaceutica International AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2018-2023)

    Figure 61. Bottom-up and Top-down Approaches for This Report

    Figure 62. Data Triangulation

    Figure 63. Key Executives Interviewed